Reduced intensity conditioning for allogeneic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: Where do we stand?

被引:12
|
作者
Anderlini, Paolo [1 ]
Champlin, Richard E. [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA
关键词
reduced-intensity conditioning; allogeneic stem cell transplantation;
D O I
10.1016/j.bbmt.2006.03.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Allogeneic stem cell transplantation following myeloablative conditioning in relapsed and refractory Hodgkin lymphoma (HL) has been associated with substantial transplant-related morbidity and mortality, as well as high relapse rates. Despite these problems, a minority of patients have experienced long-term remissions and presumably cure. As in other hematologic malignancies, reduced intensity conditioning (RIC) has now been introduced as an alternative approach. The published experience with RIC in HL patients is reviewed. While early transplant-related morbidity and mortality seem markedly reduced and preliminary data on patient outcome look promising, this remains a challenging area and additional work be needed to clearly define the role of RIC in relapsed and refractory HL. (C) 2006 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:599 / 602
页数:4
相关论文
共 50 条
  • [31] Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen
    Anderlini, P
    Saliba, R
    Acholonu, S
    Okoroji, GJ
    Donato, M
    Giralt, S
    Andersson, B
    Ueno, NT
    Khouri, I
    De Lima, M
    Hosing, C
    Cohen, A
    Ippoliti, C
    Romaguera, J
    Rodriguez, MA
    Pro, B
    Fayad, L
    Goy, A
    Younes, A
    Champlin, RE
    BONE MARROW TRANSPLANTATION, 2005, 35 (10) : 943 - 951
  • [32] Outcomes of autologous stem cell transplantation with CEAM conditioning in relapsed or refractory Hodgkin's lymphoma
    Hedayati-Asl, A. A.
    Mehrvar, A.
    Tashvighi, M.
    Faranoush, M.
    Fallah, V.
    Zangooei, R.
    Nikfarjam, H.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S373 - S373
  • [33] Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen
    P Anderlini
    R Saliba
    S Acholonu
    G-J Okoroji
    M Donato
    S Giralt
    B Andersson
    N T Ueno
    I Khouri
    M De Lima
    C Hosing
    A Cohen
    C Ippoliti
    J Romaguera
    M A Rodriguez
    B Pro
    L Fayad
    A Goy
    A Younes
    R E Champlin
    Bone Marrow Transplantation, 2005, 35 : 943 - 951
  • [34] Autologous stem cell transplantation in refractory or relapsed Hodgkin lymphoma
    Afonso, S.
    Carvalhais, I.
    Carneiro, A.
    Araujo, J.
    Principe, F.
    Guimaraes, J. E.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S440 - S441
  • [35] Allogeneic Stem Cell Transplantation for Relapsed and/or Refractory Hodgkin Lymphoma: A Multicenter Real World Experience
    Koyun, Derya
    Sahin, Ugur
    Seval, Guldane Cengiz
    Sahin, Deniz Goren
    Gokmen, Ayla
    Bozdag, Sinem Civriz
    Toprak, Selami Kocak
    Topcuoglu, Pervin
    Yuksel, Meltem Kurt
    Arslan, Onder
    Demirer, Taner
    Gurman, Gunhan
    Ilhan, Osman
    Beksac, Meral
    Ozcan, Muhit
    Arat, Mutlu
    BLOOD, 2023, 142
  • [36] Cyclosporine A and Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation for Relapsed Angioimmunoblastic T cell Lymphoma with Hemophagocytic Syndrome
    Matsumura, Yayoi
    Kuroda, Junya
    Shimura, Yuji
    Kiyota, Miki
    Yamamoto-Sugitani, Mio
    Kobayashi, Tsutomu
    Matsumoto, Yosuke
    Horiike, Shigeo
    Taniwaki, Masafumi
    INTERNAL MEDICINE, 2012, 51 (19) : 2785 - 2787
  • [37] ALLOGENEIC STEM CELL TRANSPLANTATION AND BRENTUXIMAB VEDOTIN IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A MULTICENTER EXPERIENCE
    Festuccia, M.
    Busca, A.
    Zallio, F.
    Sorasio, R.
    Brunello, L.
    Maffini, E.
    Dellacasa, C.
    Passera, R.
    Iovino, G.
    Aydin, S.
    Mordini, N.
    Pini, M.
    Boccadoro, M.
    Bruno, B.
    Giaccone, L.
    HAEMATOLOGICA, 2016, 101 : 320 - 320
  • [38] DIFFICULT TREATMENT PATHWAY IN A RELAPSED AND REFRACTORY HODGKIN LYMPHOMA CASE: ALLOGENEIC STEM CELL TRANSPLANTATION
    Karadurmus, N.
    Yildiz, B.
    Erturk, I.
    Ozaydin, S.
    LEUKEMIA RESEARCH, 2016, 49 : S49 - S50
  • [39] Safety and Efficacy of Myeloablative Conditioning Autologous Stem Cell Transplantation, Targeted Immunotherapy, and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Children, Adolescents, and Young Adults with Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
    Gardenswartz, Aliza
    Mehta, Brinda
    El-Mallawany, Nader
    van de Ven, Carmella
    Hochberg, Jessica
    Flower, Allyson
    Morris, Erin
    Harrison, Lauren
    Basso, Jaclyn
    Gerard, Perry
    Ayello, Janet
    Baxter-Lowe, Lee Ann
    Cairo, Mitchell S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [40] Allogeneic peripheral blood stem cell transplantation after a reduced conditioning regimen in refractory or relapsed Hodgkin's disease.
    Sureda, A
    Seyfarth, B
    Canals, C
    Fernández-Avilés, F
    Caballero, MD
    Hernández-Navarro, F
    Arranz, R
    Díez, JL
    Sanz, G
    Solano, C
    Martino, R
    Rovira, M
    Schmitz, N
    BLOOD, 2001, 98 (11) : 412A - 412A